Abstract
Disorders of voluntary movement are common neurological problems that have unusual importance to both clinician and scientist. Movement disorders are important to the clinician because they are generally among the most treatable neuropsychiatric disorders, yet are also among the most frequent iatrogenic complications of drug therapies. Thus, the clinician is in a powerful position both to create and to alleviate movement disorders. Proper understanding of these conditions will help the clinician distinguish spontaneously occurring diseases from the ones he creates with drugs. Proper understanding of neuro-pharmacology will help the clinician to use drug treatments to alleviate movement disorders while avoiding or reducing complications from improper drug usage. For the neuroscientist, movement disorders represent simultaneously the greatest triumphs as well as the greatest failures of basic brain research. The triumphs include the first breakthroughs in applications of neurotransmitter mechanisms to neuronal functioning. Knowledge of basal ganglia anatomy, biochemistry, and pharmacology has led, for example, to the development of treatments for Parkinson’s disease. On the other hand, the failures include the production of unwanted movement disorders by numerous drugs, including the irreversible and disabling disease tardive dyskinesia. Understanding these lessons, both good and bad, from the field of movement disorders puts the basic scientist in a strong position to develop future treatments for other disorders of the human central nervous system.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Adams, R. D., and Victor, M., 1981, Principles of Neurology, McGraw-Hill, New York.
Ayd, F. J., 1961, A survey of drug induced extrapyramidal reactions, J.A.M.A. 175:1054–1060.
Baldessarini, R. J., and Tarsy, D., 1978, Tardive dyskinesia, in: Psychopharmacology: A Generation of Progress ( M. A. Lipton, A. Dimascio, and K. R. Killam, eds.), pp. 993–1004, Raven Press, New York.
Barbeau, A., Chase, T. N., and Paulson, G. W. (eds.), 1973, Huntington’s Chorea, 1872–1972, Advances in Neurology Series, Vol. 1, Raven Press, New York.
Barbeau, A., Growdon, J. H., and Wurtman, R. J. (eds.), 1979, Nutrition and the Brain, Volume 5, Choline and Lecithin in Brain Disorders, Raven Press, New York.
Barchas, J. D., Berger, P. A., Ciaranello, R. D., and Elliott, G. R. (eds.), 1977, Psychopharmacology: From Theory to Practice, Oxford University Press, New York.
Barnes, T. R. E., and Braude, W. M., 1985, Akathisia variants and tardive dyskinesia, Arch. Gen. Psychiatry, 42: 874–878.
Berger, P. A., and Rexroth, K., 1980, Tardive dyskinesia: Clinical, biological and pharmacological perspectives, Schizophr., Bull. 6: 102–116.
Bing, R., 1923, Ueber einige bemerkenswerte begleitersche inungen der “extrapyramidalen rigiditat (akathisie-mikrographie-kinesia paradoxa), Schweiz. Med. Wochenschr. 4: 167–171.
Bing, R., 1939, Textbook of Nervous Diseases, 5th ed., Haymaker, W. (translation and enlarged), pp. 169, 758–759, Henry Limpton Press, London.
Bird, E. D., 1980, Chemical pathology of Huntington’s Disease, Ann. Rev. Pharmacol. Toxicol. 20: 533–551.
Bonduellle, M., and Degos, C., 1976, Symptomatic narcolepsies: A critical study, in: Narcolepsy ( C. Guilleminault, W. C. Dement, P. Passauant, eds.), pp. 313–332, Spectrum Publications, Inc., New York.
Braude, W. M., Barnes, T. R. E., and Gore, S. M., 1983, Clinical characteristics of akathisia: A systematic investigation of acute psychiatric inpatient admissions. Br. J. Psychiatry 143: 139150.
Caine, D. B., Chase, T. N., and Barbeau, A. (eds), 1975, Dopaminergic Mechanisms, Advances in Neurology Series, Vol. 9, Raven Press, New York.
Caine, D. M., (ed.), 1973, Progress in the Treatment of Parkinsonism, Advances in Neurology Series, Vol. 3. Raven Press, New York.
Casey, D. E., 1980, Pharmacology of blepharospasm-oromandibular dystonia syndrome, Neurology 30: 690–695.
Casey, D. E., Gerlach, J., Magelund, G., and Christensen, T. R., 1980, Gamma-acetylenic GABA in tardive dyskinesia. Arch. Gen. Psychiatry 37: 1376–1379.
Chadwick, D., Hallett, M., Harris, R., Jenner, P., Reynolds, E. H., and Marsden, C. D., 1977, Clinical, biochemical and physiological features distinguishing myoclonus responsive to 5hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam, Brain 100: 455–487.
Chase, T. N., Wexler, N. S., Barbeau, A. (eds.), 1979, Huntington’s Disease, Advances in Neurology Series, Vol. 23, Raven Press, New York.
Cohen, D. J., Young, J. G., Nathanson, J. A., and Shaywitz, B. A., 1979, Clonidine in Tourette’s syndrome, Lancet 2: 551–553.
Cohen, D. J., Detlor, J., Young, J. G., and Shaywitz, B. A., 1980, Clonidine ameliorates Gilles de la Tourette syndrome, Arch. Gen. Psychiatry 37: 1350–1357.
Critchley, E., 1949, Observations on essential (heredofamilial) tremor, Brain 72:113–139. Critchley, E., 1972, Clinical manifestations of essential tremor, J. Neurol. Neurosurg. Psychiatry 35: 365–372.
Davidson, A. B., Bofe, E., MacNeil, D. A., and Cock, L., 1983, Pharmacologic effects of R0221319: A new antipsychotic agent, Psychopharmacology 79: 32–39.
Davis, K. L., and Berger, P. A., 1978, Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis, Biol. Psychiatry 13: 23–49.
Davis, K.L., and Berger, P.A. (eds.), 1979, Brain Acetylcholine and Neuropsychiatric Disease, Plenum Press, New York.
Davis, K. L., Hollister, L. E., Berger, P. A., and Barchas, J. D., 1975, Cholinergic imbalance hypotheses of psychoses and movement disorders: Strategies for evaluation, Psychopharmacol. Commun. 1: 533–543.
Davis, K. L., Hollister, L. E., Barchas, J. D., and Berger, P. A., 1976, Choline in tardive dyskinesia and Huntington’s disease, Life Sci. 19: 1507–1516.
DeVeaugh-Geiss, J., 1980, Tardive Tourette syndrome, Neurology 30: 562–563.
DeVeaugh-Geiss, J. (ed.), 1982, Tardive Dyskinesia and Related Involuntary Movement Disorders, John Wright, Boston.
Ekbom, K. W., 1944, Asthensia Crurum parathestica (irritable legs), Acta Med. Scand. 118: 197.
Ekbom, K. A., 1960, Restless legs syndrome, Neurology 10: 868–873.
Eldridge, R., and Fahn, S. (eds.), 1976, Dystonia, Advances in Neurology Series, Vol. 14, Raven Press, New York.
Fahn, S., 1979, Treatment of dystonia with high-dosage anticholinergic medication, Neurology 29: 605.
Fann, W. E., Lake, C. R., Gerber, C. J., and McKenzie, G. M., 1974, Cholinergic suppression of tardive dyskinesia, Psychopharmacology 37: 101–107.
Fann, W. E., Smith, R. C., Davis, J. M., and Domino, E. F. (eds.), 1980, Tardive Dyskinesia, SP Medical and Scientific Books, New York.
Fog, R., and Pakkenberg, H., 1980, Theoretical and clinical aspects of the Tourette Syndrome (chronic multiple tics), J. Neural. Transm. 16 (Suppl): 211–215.
Foster, N. L., Chase, T. N., Denaro, A., Hare, T. A., and Tamminga, C. A., 1983, THIP treatment of Huntington disease, Neurology 33: 637–639.
Freedman, D. X., and DeJong, J., 1961a, Thresholds for drug-induced akathisia, Am. J. Psychiatry 117: 930–931.
Freedman, D. X. and DeJong, J., 1961b, Factors that determine drug-induced akathisia, Dis. Nerv. Sys. 22: 2–8.
Friedhoff, A., and Chase, T. N. (eds.), 1982, Tourette Syndrome, Advances in Neurology Series, Raven Press, New York.
Gardos, G., Cole, J. O., and Tarsy, D., 1978, Withdrawal syndromes associated with antipsychotic drugs Am. J. Psychiatry 135: 1321–1324.
Gelenberg, A. J., Doller-Wojcik, J. C., and Growdon, J. H., 1979, Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study. Am. J. Psychiatry 36: 772–776.
Gerlach, J., Reisby, N., and Randrup, A., 1974, Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia, Psychopharmacology 34: 21–25.
Gold, M. S., Redmond, D. E., and Kleber, H. D., 1978, Clonidine blocks acute opiate-withdrawal symptoms, Lancet 2: 599–602.
Gold, M. S., Pottash, A. C., Annitto, W. J., Extein, I., and Kleber, H. D., 1981, Lofexidine, a clonidine analogue effective in opiate withdrawal, Lancet 1: 992–993.
Gold, M. S., Pottash, A. C., and Extein, I., 1982, Clonidine: inpatient studies from 1978 to 1981, J. Clin. Psychiatry 43(6)(sec. 2 ): 35–38.
Goodman, L. S., and Gilman, A. (eds.), 1982, The Pharmacological Basis of Therapeutics, Macmillan, New York.
Groves, P. M., 1983, A theory of the functional organization of the neostriatum and the neostriatal control of voluntary movement, Brain Res. Rev. 5: 198–132.
Growdon, J. H., and Wurtman, R. J., 1979, Oral choline administration to patients with Hunting-ton’s Disease, in: Huntington’s Disease. Advances in Neurology Series, Vol. 23 ( T. N. Chase, N. S. Wexler, and A. Barbeau, eds.), pp. 765–776, Raven Press, New York.
Halaris, A. E., 1983, The use of lithium in psychiatric practice, Psychiatry Ann. 12: 53–64.
Haskovec, L., 1904, Weitere bemerkungen ueber die akathisie, Wien. Med. Wochenschr. 54: 526–530.
Heikkila, R. E., Hess, A., and Duvoisin, R. C., 1984, Dopaminergic neurotoxicity of 1-methyl-4phenyl-1,2,5,6-tetrahydropyridine in mice, Science 224: 1451–1453.
Hollister, L. E., 1978, Tricyclic antidepressants. N. Engl. J. Med. 299: 1168–1172.
Howard, F. M., 1963, A new and effective drug in the treatment of the stiff-man syndrome: preliminary report, Mayo Clin. Proc. 38: 203–212.
Iversen, L. L., 1975, Dopamine receptors in the brain, Science 188: 1084–1089.
Iversen, L. L., 1983, Neuropeptides—What next? Trends Neurosci. 6: 293–294.
Jacquet, Y. F., and Abrams, G. M., 1982, Postural asymmetry and movement disorder after unilateral microinjection of adrenocorticotropin I-24 in rat brainstem, Science 218: 175–177.
Jeste, D. V., Potkin, S. G., Sinha, S., Feder, S., and Wyatt, R. J., 1979, Tardive dyskinesiareversible and persistent, Arch. Gen. Psychiatry 36: 585–590.
Kebabian, J. W., and Caine, D. B., 1979, Multiple receptors for dopamine, Nature 277: 93–96.
Kendler, K. S., 1976, A medical student’s experience with akathisia, Am. J. Psychiatry, 133: 4.
Keretesy, A., 1967, Paroxysmal kinesigenic choreoathetosis, Neurology 17: 680–684.
Kirk, L., Baastrup, P. C., and Schou, M., 1972, Propranolol and lithium-induced tremor, Lancet 1: 839.
Klawans, H. L., 1973, The Pharmacology of Extrapyramidal Movement Disorders, Karger, Basel. Klawans, H. L., and Rubovits, R., 1972, Central cholinergic-anticholinergic antagonism in Huntington’s chorea, Neurology 22: 107–112.
Klawans, H. L., and Rubovits, R., 1974, Effect of cholinergic and anticholinergic agents on tardive dyskinesia, J. Neurol. Neurosurg. Psychiatry 27: 941–947.
Klawans, H. L., Falk, D. K., Nausieda, P. A., and Wiener, W. J., 1978, Gilles de la Tourette syndrome after long-term chlorpromazine therapy, Neurology 28: 1064–1066.
Korczyn, A. D., 1978, The pathophysiology of dystonia, J. Neural. Transm. 42: 245–250.
Langston, J. W., Ballard, P., Tetrud, J. W., and Irwin, I., 1983, Chronic parkinsonism in humans due to a product of meperidine-analog synthesis, Science 219: 979–980.
Langston, J. W., Irwin, I., Langston, E. B., and Forno, L. S., 1984, Pargyline prevents MPTPinduced Parkinsonism in primates, Science 255: 1480–1482.
Lewin, R., 1984a, Trail of ironies to Parkinson’s disease: Sloppy chemical synthesis by an illicit drug producer has led to important insights into the basic cause of Parkinson’s disease, Science 224: 1083–1085.
Lewin, R., 1984b, Brain enzyme is the target of drug toxin: A chemical known as MPTP causes a Parkinson-like state in humans and monkeys; biochemical and autoradiographical studies are closing in on the mechanism, Science 225: 1460–1462.
Lewis, B. V., and Parsons, M., 1966, Chorea gravidarum, Lancet 1: 284.
LeWitt, P. A., Newman, R. P., Miller, L. P., Lovenberg, W., and Eldridge, R., 1983, Treatment of dystonia with tetrahydrobiopterin, N. Engl. J. Med. 308: 157–158.
Luchins, D. J., Freed, W. J., and Wyatt, R. J., 1980, The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs, Am. J. Psychiatry 137: 1395–1398.
Lundberg, J. M., and Hokfelt, T., 1983, Coexistence of peptides and classical neurotransmitters, Trends Neurosci. 6: 325–333.
Magnussen, I., Dupont, E., Engback, F., and de Fine Olivarius, B., 1978, Posthypoxic intention myoclgnus treated with 5-hydroxytryptophan and an extracerebral decarboxylase inhibitor, Acta Neurolog. Scand. 57: 289–294.
Marsden, C. D., 1976, Blepharospasm-oromandibular dystonia syndrome (Brueghel’s syndrome), J. Neurol. Neurosurg. Psychiatry 39: 1204–1209.
Marsden, C. D., 1982, Basal ganglia disease, Lancet 2: 21–27.
Marsden, C. D., Tarsy, D., and Baldessarini, R. J., 1975, Spontaneous and drug-induced movement disorders in psychotic patients, in: Psychiatric Aspects of Neurological Disease ( D. F. Benson and D. Blumer, eds.), pp. 219–265, Grune and Stratton, New York.
Martin, G. E., Williams, M., Pettibone, D. J., Yarbrough, G. G., Clineschmidt, B. V., and Jones, J. H., 1984, Pharmacologic profile of a novel potent direct-acting dopamine agonist, propyl-9-hydroxynaphthoxazine (+-PHNO), J. Pharmacol. Exp. Ther. 229: 569–576.
Martin, J. B., 1984, Huntington’s disease: New approaches to an old problem, Neurology 34: 1059–1072.
McDowell, F., and Barbeau, A. (eds.), 1974, Second Canadian-American Conference on Parkinson’s Disease, Advances in Neurology Series, Vol. 5, Raven Press, New York.
Meltzer, H. Y., and Stahl, S. M., 1976, The dopamine hypothesis of schizophrenia: A review, Schizophr. Bull. 2: 19–76.
Moersch, F. P., and Woltman, H. W., 1956, Progressive fluctuating rigidity and spasm (“stiff-man” syndrome): Report of a case and some observations in 13 other cases, Mayo Clin. Proc. 31: 421–427.
Moore, D. C., and Bowers, M. B., 1980, Identification of a subgroup of tardive dyskinesia patients by pharmacologic probes, Am. J. Psychiatry 137: 1202–1205.
Nakajima, T., Kurlima, I., Nakamura, K., and Davidson, A. B., 1983, Interaction of pyrroloisoquinoline antipsychotics with a D-2 dopamine receptor subtype evaluation by 3H-R022–1319 binding, Soc. Neurosci. 9: 431.
Newman, R. P., LeWitt, P. A., Raphaelson, M. I., Foster, N. L., Calne, D. B., and Chase, T. N., 1982, Dystonia: Therapy with dopaminergic ergot derivatives, Ann. Neurol. 12: 82.
Nutt, J. G., Woodward, W. R., Hammerstad, J. P., Carter, J. H., and Anderson, J. L., 1984, the “on-off’ phenomenon in Parkinson’s disease: Relation to levodopa absorption and transport, N. Engl. J. Med. 310: 483–488.
O’Flanagan, P. M., 1975, Clonazepam in the treatment of drug-induced dyskinesia, Br. Med. J. 1: 269–270.
Olafson, R. A., Mulden, D. W., and Howard, F. M., 1964, Stiff-man syndrome: A review of the literature, report of three additional cases and discussion of pathophysiology and treatment, Mayo Clin. Proc. 39: 131–143.
Olsen, G. L., Cheung, H. C., Morgan, M. D., Blount, J. F., Todaro, L., Berger, L., Davidson, A. B., and Boff, E., 1981, A dopamine model and its application in the design of a new class of rigid pyrrolo[2,3.g] isoquinoline antipsychotics, J. Med. Chem. 24: 1026–1034.
Paulson, G. W., 1973, Meige’s Syndrome, Geriatrics 27: 69–73.
Paulson, G. W., Shaw, G., and Malarkey, W. B., 1979, Huntington’s Disease, INH and prolactin levels, Adv. Neurol. 23: 797–801.
Perry, T. L., Wright, J. M., Hansen, S., and McLeod, P. M., 1979, Isoniazid therapy of Huntington’s disease, Adv. Neurol. 23: 785–796.
Quinn, N., Parkes, J. D., and Marsden, C. D., 1984, Control of on/off phenomenon by continuous intravenous infusion of levodopa, Neurology 34: 1131–1136.
Ricker, R., and Mertens, H. G., 1968, EMG phenomena in the stiff-man syndrome, Electroencephalogr. Clin. Neurosphysiol. 25: 413.
Roberts, E., Chase, T. N., Tower, D. B. (eds.), 1976, GABA in Nervous System Function, Raven Press, New York.
Rubovits, R., and Klawans, H. L., 1972, Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskinesia, Arch. Gen. Psychiatry 27: 502–507.
Schmidt, R. T., Stahl, S. M., and Spehlmann, R., 1975, A pharmacologic study of the stiff-man syndrome: Correlation of clinical symptoms with urinary 3-methoxy-4-hydroxy-phenyl glycol (MHPG) excretion, Neurology 35: 622–626.
Sedman, G., 1976, Clonazepam in the treatment of tardive oral dyskinesia, Br. Med. J. 2: 583.
Shoulson, I., Chase, T. N., Roberts, E., and van Balgooy, J. N., 1975, Huntington’s disease: Treatment with imidazole-4-acetic acid, N. Engl. J. Med. 293: 504–505.
Shoulson, I., Kartzinel, R., and Chase, T. N., 1976, Huntington’s disease: Treatment with dipropylacetic acid and gamma-aminobutyric acid, Neurology 26: 61–63.
Sovner, R., and Dimascio, A., 1977, The effect of benztropine mesylate in the rabbit syndrome and tardive dyskinesia, Am. J. Psychiatry 134: 1301–1302.
Spehlmann, R., and Stahl, S. M., 1976, Dopamine-acetylcholine imbalance in Parkinson’s disease: Possible regenerative overgrowth of cholinergic axon terminals, Lancet 1: 724–726.
Stahl, S. M., 1980, Tardive Tourette Syndrome in an autistic patient after long-term neuroleptic administration, Am. J. Psychiatry 137: 1267–1269.
Stahl, S. M., 1984, Constant drug delivery of dopamine agonists and antagonists: Possible prevention or treatment of tardive dyskinesia and levodopa dyskinesia. Abstracts of the American College of Neuropsychopharmacology Meeting, American College of Neuropsychopharmacy Press, Vanderbilt, Tennessee.
Stahl, S. M., 1985, Akathisia and tardive dyskinesia: Changing concepts, Arch. Gen. Psychiatry 42: 915–917.
Stahl, S. M., and Berger, P. A., 1981a, Physostigmine in Tourette Syndrome: evidence for cholinergie underactivity, Am. J. Psychiatry 138: 240–242.
Stahl, S. M., and Berger, P. A., 198 lb, Bromocriptine in dystonia, Lancet 2: 745.
Stahl, S. M., and Berger, P.A., 1982a, Cholinergic and dopaminergic mechanisms in Tourette syndrome, in: Tourette Syndrome. Advances in Neurology Series, Vol. 35 ( T. N. Chase and A. J. Friedhoff, eds.), pp. 141–150, Raven Press, New York.
Stahl, S. M., and Berger, P. A., 1982b, Neuroleptic effects in Tourette syndrome predict dopamine excess and acetylcholine deficiency, Biol. Psychiatry 17: 1047–1053.
Stahl, S. M., and Berger, P. A., 1982c, Bromocriptine, physostigmine and neurotransmitter mechanisms in the dystonias, Neurology 32: 889–892.
Stahl, S. M., Layzer, R. B., Aminoff, M. J., Townsend, J. J., and Feldon, S., 1980, Continuous cataplexy in a patient with a midbrain tumor: The limp man syndrome, Neurology 30: 1115–1118.
Stahl, S. M., Davis, K. L., and Berger, P. A., 1982a, Neuropharmacology of tardive dyskinesia, spontaneous dyskinesia and other dystonias, J. Clin. Psychopharmacol. 2: 32 1328.
Stahl, S. M., Yesavage, J. A., and Berger, P. A., 1982b, Pharmacologic characteristics of idiopathic orofacial dyskinesia (Meige dystonia): Differentiation from tardive dyskinesia, J. Clin. Psychiatry 43: 445–446.
Stahl, S. M., Berger, P. A., Newman, R. P., and LeWitt, P., 1984, Bromocriptine and lisuride in dystonias, Neurology 34: 135–136.
Stahl, S. M., Thornton, J. E., Simpson, M. L., Berger, P. A., and Napoliello, M., 1985a, Gammavinyl-GABA in tardive dyskinesia and other movement disorders, Biol. Psychiatry 20: 888–893.
Stahl, S. M., Faull, K. F., Barchas, J. D., and Berger, P. A., 1985b, Cerebrospinal fluid monoamine metabolites in movement disorders and normal aging, Arch. Neurol. 42: 166–169.
Stahl, S. M., Thiemann, S., Faull, K. F., Barchas, J. D., and Berger, P. A., 1985c, Neurochemistry of dopamine in Huntington Dementia and normal aging, Arch. Gen. Psychiatry,in press.
Stahl, S. M., Thornton, J. E., and Berger, P. A., 1985d, Gamma-aminobutyric acid and movement disorders: Role of gamma-vinyl-GABA, in: Clinical and Pharmacological Studies in Psychiatric Disorders (G. D. Burrows and T. R. Norman, eds.), John Libby, London, in press.
Steck, H., 1954, Le syndrome extrapyramidal et diencephalique au cours des traitments au largactil et au serpasil, Ann. Med-Psych. 112: 737–743.
Sweet, R. D., Blumberg, J., Lee, J. M., and McDowell, F. H., 1974, Propranolol treatment of essential tremor, Neurology 24: 64–67.
Tamminga, C. A., Crayton, J. W., and Chase, T. N., 1979, Improvement in tardive dyskinesia after muscimol therapy, Arch. Gen. Psychiatry 36: 595–598.
Tamminga, C. A., Smith, R. C., and Davis, J. M., 1980, The effects of cholinergic drugs on the involuntary movements of tardive dyskinesia, in: Tardive Dyskinesia ( W. E. Fann, R. C. Smith, J. M. Davis and E. E. Domino, eds.), pp. 411–418, SP Medical and Scientific Books, New York.
Tamminga, C. A., Thaker, G. K., Ferraro, T. N., and Hare, T. A., 1983, GABA agonist treatment improves tardive dyskinesia, Lancet 11: 97–98.
Tanner, C. M., Goetz, C. G., Weiner, W. J., Nausieda, P. A., Wilson, R., and Klawans, H. L., 1979, The role of cholinergic mechanisms in spasmodic torticollis, Neurology 29: 604–605.
Tanner, C. M., Goetz, C. G., Glantz, R. H., Nausieda, P. A., Weiner, W. J., and Klawans, H. L., 1981, Cholinergic mechanisms in idiopathic partial and segmented dystonias, Ann. Neurol. 10: 94.
Tarsy, D., 1976, Dopamine-acetylcholine interaction in the basal ganglia, in: Basic and Clinical Aspects of Neurotransmitter Function (W. S. Fields, ed.), pp. 1–15, S. Karger, Basel. Tarsy, D., Leopold, N., and Sax, D. S., 1974, Physostigmine in choreiform movement disorders, Neurology 24: 28–33.
Tell, G. P., Schecter, P. J., Kock-Weser, J., Cantiniaux, P., Chabannes, J-P., and Lambert, P. A., 1981, Effects of gamma-vinyl GABA, N. Engl. J. Med. 305: 581–582.
Tolosa, E. S., and Lai, C., 1979, Meige disease: Striatal dopaminergic preponderance, Neurology 29: 1126–1130.
Uhr, S. B., Berger, P. A., Pruitt, B., and Stahl, S. M., 1984, R022–1319, a D-2 receptor antagonist for the treatment of Tourette syndrome, N. Engl. J. Med. 311: 989.
Uhr, S. B., Pruitt, B., Berger, P. A., and Stahl, S. M., 1985, Case report of four patients with Tourette syndrome treated with piquindone, a D-2 receptor antagonist, J. Clin. Psychophamacol. in press.
Urquhart, J., Fara, J. W., and Willis, K. L., 1984, Rate-controlled delivery systems in drug and hormone research, Ann. Rev. Pharmacol. Toxicol. 24: 199–236.
Van Putten, T., 1975, The many faces of akathisia, Compr. Psychiatry 16: 43–47.
Van Putten, T., May, P. R. A., and Marder, S. R., 1985, Akathisia with haloperidol and thiothixene, Arch. Gen. Psychiatry,in press.
Van Woert, M. H., Rosenbaum, D., Howieson, J., and Bowers, M. B., 1977, Long-term therapy of myoclonus and other neurological disorders with L-5-hydroxytryptophan and carbidopa, N. Engl. J. Med. 296: 70–75.
Victor, M., 1966, Treatment of alcoholic intoxication and the withdrawal syndrome. A critical analysis of the use of drugs and other forms of therapy, Psychosom. Med. 28 (4, part 2): 636–650.
Villaneuve, A., Jus, K., and Jus, A., 1973, Polygraphic studies of tardive dyskinesia and of the rabbit syndrome during different stages of sleep, Biol. Psychiatry 6: 259–274.
Washton, A. M., and Resnick, R. B., 1982, Outpatient opiate detoxification with clonidine, J. Clin. Psychiatry 436 (sec. 2): 39–41.
Washton, A. M., Resnick, R. B., Perzel, J. F., and Garwood, J., 1981, Lofexidine, a clonidine analogue effective in opiate withdrawal, Lancet 1: 991–992.
Weiss, K. J., Ciranlo, D. A., and Shader, R. I., 1980, Physostigmine test in the rabbit syndrome and tardive dyskinesia, Am. J. Psychiatry 137: 627–628.
Weissberg, M. P., and Friedrich, E. V., 1978, Sydenham’s chorea: Case report of a diagnostic dilemma, Am. J. Psychiatry 135: 607–609.
Wells, C. E., and Duncan, G. W., 1980, Neurology for Psychiatrists, F. A. Davis, Philadelphia. Yahr, M. D. (ed.), 1973, The Treatment of Parkinsonism—The Role of DOPA Decarboxylase Inhibitors, Advances in Neurology Series, Vol. 2, Raven Press, New York.
Young, R. R., and Delwaide, P. J., 1981, Drug therapy of spasticity, N. Engl. J. Med. 304: 28–33.
Zilm, D. H., Sellers, E. M., and MacLeod, S. M., 1975, Propranolol effect on tremor in alcohol withdrawal, Ann. Intern. Med. 83: 234–236.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Publishing Corporation
About this chapter
Cite this chapter
Stahl, S.M. (1986). Introduction Neuropharmacology of Movement Disorders. In: Shah, N.S., Donald, A.G. (eds) Movement Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5038-5_1
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5038-5_1
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5040-8
Online ISBN: 978-1-4684-5038-5
eBook Packages: Springer Book Archive